Stock Price Quote

STRIDES PHARMA SCIENCE LTD.

NSE : STARBSE : 532531ISIN CODE : INE939A01011Industry : Pharmaceuticals & DrugsHouse : Private
BSE807.10-22.5 (-2.71 %)
PREV CLOSE ( ) 829.60
OPEN PRICE ( ) 828.85
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 16630
TODAY'S LOW / HIGH ( )800.05 834.50
52 WK LOW / HIGH ( )268.4 838.1
NSE807.25-22.85 (-2.75 %)
PREV CLOSE( ) 830.10
OPEN PRICE ( ) 822.40
BID PRICE (QTY) 807.25 (650)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 308885
TODAY'S LOW / HIGH( ) 800.10 834.75
52 WK LOW / HIGH ( )268.15 838.6
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 28-06 1990
Management Info
Arun Kumar - Chairman Arun Kumar - Managing Director
Registered Office

Address 201, Devavrata,Sector-17,Vashi,
Navi Mumbai,
Maharashtra-400703

Phone 022-27892924 / 3199

Email corpcomm@strides.com

Website www.strides.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
Listing : BSE, NSE, MCX

NEWS

29Jan Strides Pharma Science rises as its ar
Strides Pharma Science is currently trading at Rs. 694.00, up by 8.25 po..
27Jan Strides Pharma Science’s arm receives
Strides Pharma Science’s step-down wholly owned subsidiary---Strides Pha..
08Jan Strides Pharma Science inches up as it
Strides Pharma Science is currently trading at Rs. 712.75, up by 2.40 po..
06Jan Strides Pharma Science’s arm acquires
Strides Pharma Science’s wholly-owned subsidiary -- Arco Lab has acquire..
02Jan Strides Pharma Science to invest in AM
Strides Pharma Science has received an approval for investment in the se..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit25.420000000000846.8199999999966
Gross Profit 35.2000000000008 -647.600000000003
Operating Profit 743.4100000000011825.43
Net Sales 5200.1518544.96

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

NGL Fine-Chem (BSE)
peergroup  2174.05 (2.26%)
M.Cap ( in Cr)1343.13
Astrazeneca Pharma I (BSE)
peergroup  5495.90 (0.60%)
M.Cap ( in Cr)13739.75
RPG Life Sciences (BSE)
peergroup  1660.40 (1.91%)
M.Cap ( in Cr)2746.14
Windlas Biotech (BSE)
peergroup  546.65 (5.60%)
M.Cap ( in Cr)1136.95
Dishman Carbogen Amc (BSE)
peergroup  238.65 (10.10%)
M.Cap ( in Cr)3741.63

Shareholding Pattern

FI/BANKS/INSURANCE 4.47%
NON-INSTITUTION 33.75%
PROMOTERS 27.39%
MUTUAL FUNDS/UTI 13.09%
GOVERNMENT 0.01%
FII 0%

About Strides Pharma Science Ltd.

Strides Pharma Science Ltd. was incorporated in the year 1990. Its today's share price is 807.1. Its current market capitalisation stands at Rs 7417.23 Cr. In the latest quarter, company has reported Gross Sales of Rs. 18544.96 Cr and Total Income of Rs.19543.16 Cr. The company's management includes Manjula Ramamurthy, Badree Komandur, Homi Rustam Khusrokhan, Bharat D Shah, S Sridhar, Kausalya Santhanam, Arun Kumar, Arun Kumar.

It is listed on the BSE with a BSE Code of 532531 , NSE with an NSE Symbol of STAR and ISIN of INE939A01011. It's Registered office is at 201, Devavrata,Sector-17,VashiNavi Mumbai-400703, Maharashtra. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are BSR & Co LLP, Deloitte Haskins & Sells, Deloittee Haskins & Sells, Shivadas Kallianpur & Associates, SR Batliboi & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.